SciClone China CEO Mark Lotter On The Changing Commercial Landscape: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Considered one of the top commercial minds in China, the former AstraZeneca exec and founder of NovaMed discusses how to build a sustainable commercial model in a rapidly changing China, touching on everything from retaining talent to surviving China’s latest round of price cuts.
You may also be interested in...
Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?
HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.